Solésence Makes Strategic Leap: Nasdaq Uplisting Signals Major Growth Phase

Solésence, Inc. is entering a new chapter in its corporate evolution. The company, previously trading on OTCQB under ticker NANX, has secured approval from Nasdaq’s Listing Qualifications Department to transfer its listing to the Nasdaq Capital Market. Trading under the new ticker symbol “SLSN” officially commenced on Tuesday, April 8, 2025.

This transition represents more than a symbolic milestone—it reflects the company’s achievement of all mandatory requirements for public listing on Nasdaq’s Capital Market. For shareholders, the uplisting requires no action; the transfer occurs seamlessly as the company’s securities transition from OTCQB to the larger exchange.

What This Means for Solésence’s Market Position

The Nasdaq uplisting amplifies Solésence’s visibility among institutional and retail investors alike. Operating at the intersection of beauty and life science, Solésence has carved out a distinctive niche through its mineral-based sun protection innovations. The company’s portfolio centers on redefining how skin protection integrates with beauty, combining transparency, effectiveness, and wearability in ways the sector hasn’t traditionally prioritized.

Kevin Cureton, Chief Operating Officer, emphasized the strategic importance: “This milestone was achieved through our team’s relentless efforts to profitably achieve our mission, our brand partners’ collaboration in driving growth at a multiple of the industry’s growth rate, and the patience and resilience of our shareholders.” He further noted that the Nasdaq listing may eventually provide resources enabling the company to scale profitability in ways unavailable to most competitors.

Expanded Investor Access and Strategic Implications

Jess Jankowski, President and CEO, highlighted the broader implications: “Solésence continues to redefine mineral-based sun protection as beauty brands recognize the novel skin health benefits from our award-winning products. We believe that trading on Nasdaq will increase our visibility within the investment community, broaden our shareholder base, and deliver greater value to our stakeholders.”

The Nasdaq uplisting marks a turning point for a company built on scientifically-driven health care solutions. By integrating protection, prevention, and treatment technologies into daily-use products, Solésence has positioned itself to deliver distinctive product claims for brand partners. This operational model, combined with greater market exposure, positions the company to accelerate both growth and profitability trajectories.

The transition underscores how capital market access influences competitive dynamics in the health and beauty sector—particularly for companies pioneering novel formulation science.